PHASE 2 RANDOMIZED STUDY (ORION-1) OF A NOVEL, BIODEGRADABLE DEXAMETHASONE IMPLANT (AR-1105) FOR THE TREATMENT OF MACULAR EDEMA DUE TO CENTRAL OR BRANCH RETINAL VEIN OCCLUSION

AR-1105 is a novel biodegradable sustained-release dexamethasone implant designed to deliver 6-month durability. This Phase 2 study evaluated two AR-1105 formulations with different release profiles in patients with macular edema due to retinal vein occlusion. METHODS: Patients received a single int...

Descripción completa

Detalles Bibliográficos
Autores principales: Singer, Michael A., Boyer, David S., Williams, Stuart, McKee, Hayley, Kerr, Kevin, Pegoraro, Tyler, Trevino, Leo, Kopczynski, Casey C., Hollander, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Retina 2023
Materias:
Original Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750099/
https://www.ncbi.nlm.nih.gov/pubmed/36542081
http://dx.doi.org/10.1097/IAE.0000000000003632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750099/
https://www.ncbi.nlm.nih.gov/pubmed/36542081
http://dx.doi.org/10.1097/IAE.0000000000003632

Ejemplares similares